Contact Us for our BEST PRICE Now! +44 7887 945 155 Email Us
Follow RSS for latest reports on this topicSteatohepatitis - Market Research and Reports
Steatohepatitis fatty liver disease) is a type of liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Seen in alcoholics as part of alcoholic liver disease, steatohepatitis also is frequently found in people with diabetes and obesity and it is related to metabolic syndrome. When not associated with excessive alcohol intake, it is referred to as nonalcoholic steatohepatitis, or NASH and is the progressive form of the relatively benign non-alcoholic fatty liver disease
Steatohepatitis of either etiology may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis. NASH is also associated with lysosomal acid lipase deficiency.
Source: Wikipedia
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.
Related Reports:
We found 37 reports that matched your search.
Refine your search, and find more matches, using the form above.
Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020
Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020SummaryGlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H2, 2020 provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Repor...Read More >>>
Published:
2020-09-01
Published by: Global Data
Prices Starting From:
$2125
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2020, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the...Read More >>>
Published:
2020-07-31
Published by: Global Markets Direct
Prices Starting From:
$2125
Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029
Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029SummaryNon-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2016). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symp...Read More >>>
Published:
2020-06-15
Published by: Global Data
Prices Starting From:
$3396
Nash Market: Nonalcoholic Steatohepatitis - Pipeline Review-2019
Firstview Insight's Nash Market: Nonalcoholic Steatohepatitis - Pipeline Review-2019 provides an overview of the pipeline landscape of Nash Market: Nonalcoholic Steatohepatitis It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage th...Read More >>>
Published:
2019-12-20
Published by: First View Insight
Prices Starting From:
$1063
Nash Market: Nonalcoholic Steatohepatitis - Pricing & Market Access and Landscape- 2019
Firstview Insight's Nash Market: Nonalcoholic Steatohepatitis - Pricing & Market Access and Landscape- 2019 provides country specific insights in order to estimate market potential for Nash Market: Nonalcoholic Steatohepatitis based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet ...Read More >>>
Published:
2019-12-20
Published by: First View Insight
Prices Starting From:
$2125
Nash Market: Nonalcoholic Steatohepatitis - Market Review, Epidemiology And Market Forecast - 2029
FirstView Market Insight Nash Market: Nonalcoholic Steatohepatitis - Market Review, Epidemiology And Market Forecast - 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights.The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, mark...Read More >>>
Published:
2019-12-20
Published by: First View Insight
Prices Starting From:
$2975
Global Non-alcoholic Steatohepatitis Market Research (2015-2019) and Future Forecast (2020-2025)
SummaryThe report forecast global Non-alcoholic Steatohepatitis market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025.The report offers detailed coverage of Non-alcoholic Steatohepatitis industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the lead...Read More >>>
Published:
2019-12-16
Published by: 99Strategy
Prices Starting From:
$2805
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2019
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2019, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup...Read More >>>
Published:
2019-11-29
Published by: Global Markets Direct
Prices Starting From:
$2125
Non-Alcoholic Steatohepatitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020
GervanoRA’s Pipeline Drug Analytics Report Non-Alcoholic Steatohepatitis Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020 provides a detailed overview on Non-Alcoholic Steatohepatitis Competitive Space. Report provides deep insights on pipeline analytics outlook, drivers, restraints and unmet needs of Non-Alcoholic Steatohepatitis pi...Read More >>>
Published:
2019-08-21
Published by: Gervano R A
Prices Starting From:
$1063
Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2012-2024
SummaryThe global Nonalcoholic Steatohepatitis (NASH) market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the r...Read More >>>
Published:
2019-05-21
Published by: HeyReport
Prices Starting From:
$1930
2019 Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025
The global clinical trial report- “2019 Non-Alcoholic Steatohepatitis (NASH) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Non-Alcoholic Steatohepatitis (NASH). It presents in-depth analysis of Non-Alcoholic Steatohepatitis (NASH) clinical trials across markets and companies. The research work is for providing complete understanding into trends in ...Read More >>>
Published:
2019-04-24
Published by: VPA Research
Prices Starting From:
$1529
2019 Steatohepatitis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025
The global clinical trial report- “2019 Steatohepatitis Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Steatohepatitis. It presents in-depth analysis of Steatohepatitis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Steatohepatitis. The report covers a key snapshot of trial tren...Read More >>>
Published:
2019-04-24
Published by: VPA Research
Prices Starting From:
$1529
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup...Read More >>>
Published:
2019-04-23
Published by: Global Markets Direct
Prices Starting From:
$2125
Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market
Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the MarketSummaryNon-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. Globally, the NAFLD prevalence rate is estimated to be around 25% and a significant p...Read More >>>
Published:
2018-12-03
Published by: GBI Research
Prices Starting From:
$4246
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)SummarySociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the NASH market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher - - Executive Summary: Contains analysis of key market even...Read More >>>
Published:
2018-11-30
Published by: Global Data
Prices Starting From:
$5440
Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026
Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026SummaryNon-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD...Read More >>>
Published:
2018-09-28
Published by: Global Data
Prices Starting From:
$7221
Steatohepatitis Global Clinical Trials Review, H2, 2018
Steatohepatitis Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, “Steatohepatitis Global Clinical Trials Review, H2, 2018 provides an overview of Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countrie...Read More >>>
Published:
2018-08-31
Published by: Global Data
Prices Starting From:
$2125
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup...Read More >>>
Published:
2018-07-17
Published by: Global Markets Direct
Prices Starting From:
$1700
Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018
Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis (NASH) Global Clinical Trials Review, H1, 2018 provides an overview of Non-Alcoholic Steatohepatitis (NASH) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Repor...Read More >>>
Published:
2018-03-31
Published by: Global Data
Prices Starting From:
$2125
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018SummaryThis report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players active in this space, and als...Read More >>>
Published:
2018-03-22
Published by: GBI Research
Prices Starting From:
$3396
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Non-Alcoholic Steatohepatitis (NASH) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with comple...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$1700
Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2027
DelveInsight's Nonalcoholic Steatohepatitis (NASH) - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Nonalcoholic Steatohepatitis (NASH) epidemiology and market outlook for the 7MM.Markets Covered• United States• EU5 (Germany, France, Italy, Spain, and the United Kingdom)• JapanStudy Period: 2016-2027Nonalcoholic Steatohepatitis (NASH) ...Read More >>>
Published:
2018-02-14
Published by: Delve Insight
Prices Starting From:
$5313
Global and Chinese NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry, 2017 Market Research Report
The 'Global and Chinese NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers industry with a focus on the Chinese market. The report provides key statistics on the market status of the NASH (Non-alcoholic Steatohepatitis) Biomarkers manufact...Read More >>>
Published:
2017-12-15
Published by: Prof Research
Prices Starting From:
$2550
Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast – 2027
DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology and Market Forecast-2027’ report provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan. The Report covers the therapeutics market revenue, treatment p...Read More >>>
Published:
2017-09-01
Published by: Delve Insight
Prices Starting From:
$4888
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2017
DelveInsight’s, “Non-Alcoholic Steatohepatitis (NASH)-Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Non-Alcoholic Steatohepatitis (NASH). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics asse...Read More >>>
Published:
2017-07-31
Published by: Delve Insight
Prices Starting From:
$1700
Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)
Executive SummaryA comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic S...Read More >>>
Published:
2017-07-25
Published by: Azoth Analytics
Prices Starting From:
$2040
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2017, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup...Read More >>>
Published:
2017-07-11
Published by: Global Markets Direct
Prices Starting From:
$1700
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver....Read More >>>
Published:
2017-02-28
Published by: Global Markets Direct
Prices Starting From:
$1700
EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025
EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025SummaryNon-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage. Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no sy...Read More >>>
Published:
2016-12-01
Published by: Global Data
Prices Starting From:
$3396
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2016 provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of tr...Read More >>>
Published:
2016-11-30
Published by: Global Data
Prices Starting From:
$2125
Steatohepatitis Global Clinical Trials Review, H2, 2016
Steatohepatitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Steatohepatitis Global Clinical Trials Review, H2, 2016 provides an overview of Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countrie...Read More >>>
Published:
2016-11-30
Published by: Global Data
Prices Starting From:
$2125
Nonalcoholic Steatohepatitis (NASH): KOL Insight
Who will benefit most from huge opportunities in NASH treatment?The first new NASH therapy is due soon: but is it safe and effective enough? How happy are KOLs with the plethora of current trials and endpoints? Which is more appealing: tackling early signs or advanced stages? With no cure in sight and issues around diagnosis, long-term safety and cost all still being hotly debated-clearly there is...Read More >>>
Published:
2016-05-01
Published by: FirstWord Pharma
Prices Starting From:
$6715
Steatohepatitis Global Clinical Trials Review, H2, 2015
Steatohepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Steatohepatitis Global Clinical Trials Review, H2, 2015 provides an overview of Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countrie...Read More >>>
Published:
2015-12-16
Published by: Global Data
Prices Starting From:
$2125
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies
Within the oral mucosal cavity, the buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and it is relatively permeable. The buccal mucosa offers several advantages for controlled drug delivery for extended periods of time. The mucosa is well supplied with both vascular and lymphatic drainage and first-pass metabolism in the liv...Read More >>>
Published:
2015-12-01
Published by: MP Advisors
Prices Starting From:
$2975
Global NASH (Non –Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) (By Region, By Drugs – Off Label & Special Treatment Drugs, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)
Executive SummaryProgressive numbers of Liver disorders along with rise in obesity will fuel the demand for NASH DrugsThe Global NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, ant...Read More >>>
Published:
2015-12-01
Published by: Azoth Analytics
Prices Starting From:
$1700
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2015 provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of tr...Read More >>>
Published:
2015-11-30
Published by: Global Data
Prices Starting From:
$2125
Nonalcoholic Steatohepatitis: KOL Insight
IntroductionWhy This Report is Essential Expect a revolution in the treatment of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment for a disease that has high unmet clinical need. Nonalcoholic Steatohepatitis: KOL Insight reveals the critical views of US and European KOLs whose insights hold key lessons for pharma. Gain insights on prod...Read More >>>
Published:
2015-03-01
Published by: FirstWord Pharma
Prices Starting From:
$6715